At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Bertilimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
In Brief
A Phase 2 clinical trial evaluating Bertilimumab for Pemphigoid, Bullous. Completed, enrolled 11 participants across 8 sites in 2 countries.
Detailed Summary
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPemphigoid, Bullous
CountriesIsrael, United States
CollaboratorsImmune Pharmaceuticals
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartFeb 2016
Primary CompletionApr 2018
TodayJul 2026
First PostedAug 27, 2014
Enrollment StartFeb 29, 2016
Primary CompletionApr 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.8 years ago
Interventions
Bertilimumabbiological